Vir Biotechnology, Inc.
VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 fā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.06
Price+0.42%
$0.03
1Y
Price
Market Cap
$842.333m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-66656.2%
EBITDA Margin-67975.4%
Net Profit Margin-69952.9%
Free Cash Flow Margin-66656.2%
EBITDA Margin-67975.4%
Net Profit Margin-69952.9%
Free Cash Flow MarginRevenue
$16.860m
-77.3%
1y CAGR-61.9%
3y CAGR-34.6%
5y CAGREarnings
-$499.653m
+4.3%
1y CAGR-66.6%
3y CAGR-50.6%
5y CAGREPS
-$3.61
+5.7%
1y CAGR-65.8%
3y CAGR-50.2%
5y CAGRBook Value
$796.098m
$1.019b
Assets$223.355m
Liabilities$100.175m
DebtDebt to Assets
9.8%
-0.2x
Debt to EBITDAFree Cash Flow
-$460.431m
-1.5%
1y CAGR-36.1%
3y CAGR+572.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company